The agreement covers the manufacture and supply of superparamagnetic particles. T2 Bio will be a non-exclusive reseller of the particles as part of its products.
The firm said it secured a record 14 new contracts of T2Dx instruments in the fourth quarter, which was at the high end of its guidance for the second half of 2018.
The firm said that the panel is expected to receive CE marking for commercial availability in Europe later this year.
A lack of attractive targets, high valuations, and a more attractive IPO market contributed to a 45 percent year-over-year decline in M&A.
During the year, the growing threat of antimicrobial resistance drove development and adoption of advanced diagnostic tests, including molecular testing.
The firm beat Wall Street analyst estimates for revenues and earnings per share in the third quarter.
Product revenues were up 63 percent year over year, while research revenues rose twelvefold. The company placed nine new T2Dx instruments in Q2 2018.
Agilent Technologies announced this week that it has agreed to acquire privately-held ProZyme, a provider of glycan analysis reagents, kits, and standards.
Alere received clearance for the Afinion HbA1c Dx and for the Alere i Strep A 2, a rapid molecular test for the qualitative detection of Streptococcus pyogenes.
The firm sold about about 7 million shares of its common stock at $7.50 per share, including 915,000 shares to the offering’s underwriters also for $7.50 per share.